TIMI Study Group
- Company typePrivate
- Founded1984
- HeadquartersBoston, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
TIMI Study Group firmographics
Firmographics- Name
- TIMI Study Group
- Legal name
- TIMI Study Group
- Website
- https://timi.org
- Company type
- Private
- Founded year
- 1984
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
TIMI Study Group industry classification
Industry- Product category
- Academic Clinical Research Organization Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (541690)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Clinical Trial Monitoring Support (On-site/Remote) (HLAGACAG)
- akta.pro secondary industries
- Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Imaging & Cardiac Safety Core Labs (ECOG/EEG/ECG) (HLAGAAAJ)
Keywords
Where TIMI Study Group is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
TIMI Study Group business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Clinical Trial Sponsorship Contracts: TIMI Study Group generates revenue through contracts with pharmaceutical and biotechnology companies to design, execute, and manage clinical trials. Sponsors include companies developing cardiovascular therapies, lipid-modifying agents, antiplatelet therapies, and other cardiovascular drugs. TIMI provides comprehensive trial services including academic leadership, global trial management, biostatistics, clinical event adjudication, safety monitoring, and core laboratory services.
- NIH and Government Research Grants: The organization also conducts trials with support from the National Institutes of Health (NHLBI), in addition to industry sponsorship.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
TIMI Study Group product offering
Product offeringCore offering
TIMI Study Group is an academic research organization that designs, executes, and manages multicenter cardiovascular clinical trials on behalf of pharmaceutical, biotechnology, and government sponsors. Service lines include academic trial leadership and protocol design, global trial management across a network of more than 5,000 investigators in 50+ countries, biostatistics and clinical prediction modeling, Clinical Events Committee adjudication, Safety Desk reporting, a 24/7 Medical Hotline, and three Core Laboratories for biomarkers, pharmacogenetics, and ECG analysis.
Product overview
TIMI Study Group is an Academic Research Organization (ARO) affiliated with Brigham and Women's Hospital and Harvard Medical School that provides a comprehensive suite of clinical trial services. The core offerings include Academic Trial Leadership for protocol design and guidance, Global Trial Management for site coordination across 50+ countries, TIMI Biostatistics for study design and advanced statistical analysis, Clinical Events Committee for endpoint adjudication, Safety Desk for regulatory-compliant event processing, Medical Hotline for 24/7 physician support, and Core Laboratories for ECG, biomarker, and pharmacogenetic analysis. Supporting tools include TIMI Calculators (interactive risk score calculators) and TIMI Talks Podcast (expert discussions on trial design and cardiology). The organization has conducted over 80 clinical trials enrolling approximately 400,000 patients since 1984.
Differentiator
Problem solved
Functional benefit
Brands
- Critical Care Cardiology Trials Network (CCCTN): A collaborative research network drawn from national leaders in critical care cardiology and coordinated by the TIMI Study Group, dedicated to advancing care of patients requiring cardiac critical care.
- TIMI Biostatistics
- TIMI Biostatistics Core
- Clinical Events Committee (CEC)
- Safety Desk
- Medical Hotline
- Core Labs
- TIMI Biomarker Program
- TIMI Genetics Program
- TIMI ECG Core Laboratory
- TIMI Talks Podcast
Products and services
- Academic Trial Leadership
- Global Trial Management
- TIMI Biostatistics
- Clinical Events Committee (CEC)
- Safety Desk
- Medical Hotline
- Core Labs (Biomarkers, Pharmacogenetics, ECG)
- TIMI Calculators
Quantifiable outcome
- Over 80 clinical trials conducted since 1984 that have shaped cardiovascular care practice
- +2 more outcomes
Companies that use TIMI Study Group
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
TIMI Study Group technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
TIMI Study Group partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Critical Care Cardiology Trials Network (CCCTN)coreThe Critical Care Cardiology Trials Network (CCCTN) is a collaborative research network drawn from national leaders in critical care cardiology and coordinated by the TIMI Study Group. The network's mission is to design and execute observational studies and clinical trials that advance the care of patients requiring cardiac critical care. The CCCTN has produced extensive publications in critical care cardiology and operates a multinational registry.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
TIMI Study Group competitors and assessment
Company assessmentBroad incumbents
- IQVIA: Largest global CRO offering full-service clinical development including biostatistics, project management, and cardiovascular trials. Competitor to TIMI for mid-tier and large pharma CV trials, but with broader therapeutic and service scope.
- Parexel International: Large global CRO with cardiovascular and biostatistics capabilities competing for pharma-sponsored trials. Broader portfolio than TIMI but overlaps on CV trial design, biostatistics, and global study management.
- ICON plc: Global CRO providing full-service clinical development including biostatistics and cardiovascular outcomes research. Comparable to TIMI on trial execution but with broader therapeutic breadth and commercial scale.
- Medpace Holdings: Mid-to-large CRO with strong cardiovascular franchise and full-service clinical development model. Competes with TIMI for biotech-sponsored CV trials, particularly in metabolic and CV outcomes research.
- Labcorp Drug Development (formerly Covance): Major global CRO with central laboratories, biostatistics, and full-service clinical trial operations. Competes with TIMI for CV trials requiring integrated core lab and project management services at scale.
Direct peers
- Duke Clinical Research Institute (DCRI): Academic research organization within Duke University School of Medicine conducting large-scale cardiovascular and other trials with biostatistics, project leadership, and core lab services. Closest scale competitor to TIMI and benchmark ARO model.
- Population Health Research Institute (PHRI): McMaster University-affiliated ARO conducting large international cardiovascular and metabolic trials with similar global site network and academic leadership structure. Direct peer in terms of trial scope, geographic reach, and CV focus.
- Canadian VIGOUR Centre: University of Alberta-affiliated cardiovascular clinical trials research organization with academic leadership model and international CV trial programs. Comparable ARO peer with similar trial leadership and investigator network orientation.
- Baim Institute for Clinical Research: Academic research organization focused on cardiovascular clinical trials with similar ARO service model (trial design, project management, biostatistics, CEC). Most directly comparable peer to TIMI in scope, structure, and CV therapeutic focus.
- Thrombosis Research Institute: London-based research institute specializing in thrombosis and cardiovascular trials with global investigator network. Comparable to TIMI's antithrombotic trial portfolio and academic research mission.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat7 records
Key risks5 records
Key highlights6 records
Customer concentration
TIMI Study Group social profiles
Digital presenceTIMI Study Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
TIMI Study Group leadership team
Management profileNumber of profiles
Profiles13 records
TIMI Study Group funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TIMI Study Group M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TIMI Study Group
What does TIMI Study Group do?
TIMI Study Group is an academic research organization that designs, executes, and manages multicenter cardiovascular clinical trials on behalf of pharmaceutical, biotechnology, and government sponsors. Service lines include academic trial leadership and protocol design, global trial management across a network of more than 5,000 investigators in 50+ countries, biostatistics and clinical prediction modeling, Clinical Events Committee adjudication, Safety Desk reporting, a 24/7 Medical Hotline, and three Core Laboratories for biomarkers, pharmacogenetics, and ECG analysis.
Is TIMI Study Group a public or private company?
TIMI Study Group is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was TIMI Study Group founded?
TIMI Study Group was founded in 1984. It employs 101 to 250 people.
Where is TIMI Study Group based?
TIMI Study Group is headquartered in Boston, United States, in the North America region.
How does TIMI Study Group make money?
Two revenue lines are on record. Clinical Trial Sponsorship Contracts are the primary driver. The others are NIH and Government Research Grants.
Who are TIMI Study Group's main competitors?
Broad incumbents on record are IQVIA, Parexel International, ICON plc, Medpace Holdings and Labcorp Drug Development (formerly Covance). Direct peers are Duke Clinical Research Institute (DCRI), Population Health Research Institute (PHRI), Canadian VIGOUR Centre, Baim Institute for Clinical Research and Thrombosis Research Institute.
Does TIMI Study Group have an API?
No public API is recorded for TIMI Study Group.
What industry is TIMI Study Group in?
TIMI Study Group's product category is Academic Clinical Research Organization Services. Its primary akta.pro industry code is HLAGACAG, Clinical Trial Monitoring Support (On-site/Remote), with a secondary code of HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its NAICS code is 5417 and its SIC code is 8731.